Clinical Research
According to the World Health Organization (WHO), respiratory tract infections rank among the most significant health challenges worldwide due to their high prevalence and associated economic cost. Children experience an average of 6 to 8 episodes of Acute Respiratory Infection (ARI) per year, a rate consistent across both developed and developing countries. While most infections affect the upper respiratory tract and manifest as common colds or coughs, their impact on quality of life and healthcare systems is substantial.
Afriplex® PS70 addresses this need with clinically validated efficacy. Numerous trials have evaluated its role in alleviating symptoms of respiratory conditions, including bronchitis, sinusitis, tonsillitis, rhinopharyngitis, and other upper respiratory tract infections. These findings are supported by the European Medicines Agency (EMA) in its herbal monograph (EMA/HMPC/444251/2015), reinforcing the therapeutic relevance of Pelargonium Sidoides root extract in modern medicine.
Clinical Trials were conducted on the symptoms of the illnesses below:
Acute Bronchitis
Efficacy and safety of an extract of Pelargonium Sidoides (EPs 7630) in adults with acute bronchitis
Clinical studies confirm the superior efficacy of Pelargonium Sidoides extract compared to placebo in the treatment of acute bronchitis in adults. Patients receiving the extract experienced a significantly shorter duration of illness, with symptoms reduced more effectively than in the placebo group. Notably, treatment with Pelargonium extract also shortened the period of work incapacity by nearly two days, highlighting its role in faster recovery and improved quality of life.
Treatment of acute bronchitis with liquid herbal drug preparation from Pelargonium Sidoides (EPs 7630): a randomised, double-blind, placebo-controlled, multicentre study
The Clinical evidence demonstrates that Pelargonium Sidoides extract delivers significant improvements in key bronchitis symptoms, including cough, chest pain during coughing, sputum production, rales/rhonchi, and dyspnoea, compared to placebo. Patient satisfaction was rated as very high, confirming both the effectiveness and tolerability of this herbal treatment. Importantly, the extract provides a safe alternative treatment for acute bronchitis in adults—especially in cases where antibiotic therapy is not indicated—making Afriplex® PS70 a valuable solution for modern respiratory care.
Treatment of Acute Bronchitis in Adults With a Pelargonium Sidoides Preparation (EPs® 7630): A Randomized, Double-Blind, Placebo-Controlled Trial
Clinical research shows that patients treated with Pelargonium Sidoides extract experienced greater improvements in health-related quality of life compared to those receiving placebo. The extract demonstrated superior efficacy in managing acute bronchitis in adults, potentially offering a safe and effective alternative when antibiotics are not clearly indicated.
Acute Sinusitis & Common Cold
Efficacy and Tolerability of High-dose Pelargonium Extract in Patients With the Common Cold
http://alternative-therapies.com/openaccess/ATHM9589Riley.pdf
After just 10 days of treatment, 63.5% of patients receiving Pelargonium Sidoides extract were clinically cured, compared to only 11.8% in the placebo group. In addition, the duration of work incapacity was significantly shorter for those treated with the extract, reinforcing a faster recovery time and a reduction in the impact of illness on daily life.
Tonsillopharyngitis
Clinical Efficacy and Safety of Liquid Pelargonium Sidoides Preparation (EPs 7630) in Children with Acute Non-Streptococcal Tonsillopharyngitis
Clinical studies on EPs 7630 in children with acute non-streptococcal tonsillopharyngitis concluded that treatment with Pelargonium Sidoides extract not only significantly reduced symptom severity but also shortened the duration of illness by at least two days compared to placebo. These findings highlight Afriplex® PS70 as a safe, effective solution for paediatric respiratory care, offering faster recovery for young patients.